by andrewmm2007 | Jan 18, 2023 | Press Releases, Featured Press 2
SAN FRANCISCO, January 18, 2023 – Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers,...
by andrewmm2007 | Jun 1, 2022 | Featured Press 2, Press Releases
First-in-class, oral cannabinoid CB2 antagonist acting as an immune checkpointinhibitor has potential to enhance immune response to treat solid tumors Company on track to initiate Phase 1/2 clinical trial in third quarter 2022 SAN FRANCISCO, June 1, 2022 – Teon...